| First Author | Hennige AM | Year | 2003 |
| Journal | J Clin Invest | Volume | 112 |
| Issue | 10 | Pages | 1521-32 |
| PubMed ID | 14617753 | Mgi Jnum | J:94000 |
| Mgi Id | MGI:3510505 | Doi | 10.1172/JCI18581 |
| Citation | Hennige AM, et al. (2003) Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 112(10):1521-32 |
| abstractText | The insulin receptor substrate-2 (Irs2) branch of the insulin/IGF signaling system coordinates peripheral insulin action and pancreatic beta cell function, so mice lacking Irs2 display similarities to humans with type 2 diabetes. Here we show that beta cell-specific expression of Irs2 at a low or a high level delivered a graded physiologic response that promoted beta cell growth, survival, and insulin secretion that prevented diabetes in Irs2-/- mice, obese mice, and streptozotocin-treated mice; and that upon transplantation, the transgenic islets cured diabetes more effectively than WT islets. Thus, pharmacological approaches that promote Irs2 expression in beta cells, especially specific cAMP agonists, could be rational treatments for beta cell failure and diabetes. |
